Economic burden of multiple myeloma among patients in successive lines of therapy in the United States

References

• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2014 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2014;89:998–1009.
   Web of Science ®Google Scholar
• National Cancer Institute [Internet]. SEER Cancer Statistics Factsheets: Myeloma. Bethesda (MD): National Cancer Institute; 2014 [cited 2016 Sep 7]. Available from: http://seer.cancer.gov/statfacts/html/mulmy.html.
   Google Scholar
• Evangelos T, Martina K, Engelhardt M, et al. European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica 2015;100:1254–1266.
   PubMed Web of Science ®Google Scholar
• Mayo Clinic [Internet]. Multiple Myeloma Complications by Mayo Clinic Staff. 2017 [cited 2016 Nov 9]. Available from: http://www.mayoclinic.org/diseases-conditions/multiple-myeloma/basics/complications/con-20026607.
   Google Scholar
• Zeng Z, Lin J, Chen J. Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Ann Hematol. 2013;92:935–943.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011;8:479–491.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962–2972.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 2009;23:2147–2152.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110:3557–3560.
   PubMed Web of Science ®Google Scholar
• Leonard CE, Freeman CP, MaCurdy T, et al. Utilization and cost of anticancer biologic products among Medicare beneficiaries, 2006–2009: Data Points #6. Data Points Publication Series [Internet]. Rockville (MD): Agency for Healthcare Research and Quality; 2011 [cited 2016 Sep 7]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK65148/.
   Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–152.
   PubMed Web of Science ®Google Scholar
• San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–1066.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–631.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. An open-label, randomised, phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX. Haematologica. 2016;101:342.
   Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): the phase 3 tourmaline-MM1 study (NCT01564537). Blood. 2015;126:727–727.
   Web of Science ®Google Scholar
• Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16:593–602.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990;322:1693–1699.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC. Supportive care in multiple myeloma. Clin Lymphoma Myeloma. 2006;7:42–50.
   PubMedGoogle Scholar
• Arikian SR, Milentijevic D, Binder G, et al. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Curr Med Res Opin. 2015;31:1105–1115.
   PubMed Web of Science ®Google Scholar
• Teitelbaum A, Ba-Mancini A, Huang H, et al. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist. 2013;18:37–45.
   PubMed Web of Science ®Google Scholar
• Gaultney JG, Franken MG, Tan SS, et al. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. J Clin Pharm Thera. 2013;38:41–47.
   PubMed Web of Science ®Google Scholar
• Barlev A. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm. 2010;16:693–702.
   PubMed Web of Science ®Google Scholar
• Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4:313–320.
   PubMed Web of Science ®Google Scholar
• Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2191–2197.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network [Internet]. NCCN Clinical Practice Guidelines in Oncology. Version 2.2015. National Comprehensive Cancer Network; 2015 [cited 2016 Sep 7]. Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
   Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–1128.
   PubMed Web of Science ®Google Scholar
• Ailawadhi S. The changing face of multiple myeloma. Am J Hematol/Oncol. 2015;11:21–25.
   Web of Science ®Google Scholar
• Durie B, Binder G, Pashos C, et al. Total cost comparison in relapsed/refractory multiple myeloma. J Med Econ. 2013;16:614–622.
   PubMedGoogle Scholar
• Kenney J. Advances in the management of multiple myeloma: implications for payers. Am Health Drug Benefits. 2011;4(2 Suppl 4):S59–S60.
   Google Scholar
• Kumar SK, Lee JH, Dimopoulos MA, et al. Outcomes after initial relapse of multiple myeloma: an International Myeloma Working Group study. Blood. 2015;126:4201–4201.
   Web of Science ®Google Scholar
• Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33:2563–2577.
   PubMed Web of Science ®Google Scholar
• Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121:4439–4442.
   PubMed Web of Science ®Google Scholar
• Cutler DM, Ghosh K. The potential for cost savings through bundled episode payments. N Engl J Med. 2012;366:1075–1077.
   PubMed Web of Science ®Google Scholar
• Congressional Budget Office [Internet]. Health-related options for reducing the deficit: 2014 to 2023. Washington (DC): Congressional Budget Office; 2013 [cited 2016 Sep 7]. Available from: http://www.cbo.gov/publication/44906.
   Google Scholar
• Porter ME. What is value in health care? N Engl J Med. 2010;363:2477–2481.
   PubMed Web of Science ®Google Scholar
• Farr AM, Stott-Miller M, Varker H, et al. Front-line (FL) treatment patterns associated with elderly newly diagnosed multiple myeloma (MM) patients treated in the US community setting. Blood. 2015;126:5360–5360.
   Google Scholar
• Lin J, Lingohr-Smith M, Omar M, et al. Survival of US Elderly Patients with Multiple Myeloma in the Community Setting. Poster session presented at: European School of Haematology 3rd International Conference on Multiple Myeloma; 2016 Oct 7–9; Milan, Italy.
   Google Scholar